IC 500 - IVERIC bio
Alternative Names: HtrA1 inhibitors - IVERIC bio; IC-500 IVERIC bioLatest Information Update: 20 Jul 2023
Price :
$50 *
At a glance
- Originator Inception 4
- Developer IVERIC bio
- Class Eye disorder therapies; Small molecules
- Mechanism of Action High-temperature requirement A serine peptidase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 20 Jul 2023 IC 500 is still in preclinical development in Dry age related macular degeneration in USA (IVERIC bio pipeline, July 2023)
- 11 Jul 2023 IVERIC bio has been acquired by Astellas Pharma
- 28 May 2023 No recent reports of development identified for preclinical development in Dry age related macular degeneration in USA (Ophthalmic, Drops)